A Phase 2, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of UBT251 Injection in Adult Patients With Metabolic Dysfunction-associated Steatohepatitis (MASH)
Latest Information Update: 09 Sep 2025
At a glance
- Drugs UBT 251 (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Therapeutic Use
- Sponsors United Bio-Technology (Hengqin)
Most Recent Events
- 09 Sep 2025 New trial record